Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Petrini

Showing results (221-230 of 254) with videos related to

Pageof 26
Sort By:
Frontiers in Pharmacology|July 15, 2017
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective StudySara Galimberti, Elena Ciabatti, Giacomo Ercolano, et al.
Epigenomics|September 8, 2015
Polycomb genes are associated with response to imatinib in chronic myeloid leukemiaFrancesco Crea, Antonello Di Paolo, Hui Hsuan Liu, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trialEmilio Iannitto, Viviana Minardi, Paolo G Gobbi, et al.
Journal of Human Genetics|January 11, 2013
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortiumAlessandro Martino, Juan Sainz, Rui Manuel Reis, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemiaLaura Galeotti, Francesco Ceccherini, Dario Domingo, et al.
Frontiers in Oncology|July 12, 2019
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid LeukemiaSusanna Grassi, Sara Palumbo, Veronica Mariotti, et al.
Muscle & Nerve|January 22, 2011
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter studyAdriano Chiò, Gabriele Mora, Vincenzo La Bella, et al.
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
International Journal of Oncology|December 14, 2011
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review)Alessandro Martino, Juan Sainz, Gabriele Buda, et al.
Cancer Cell International|April 18, 2019
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patientsSerena Salehzadeh, Francesca Guerrini, Umberto Pizzano, et al.
Pageof 26

Showing results (221-230 of 254) with videos related to

Sort By:
Pageof 26
Frontiers in Pharmacology|July 15, 2017
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective StudySara Galimberti, Elena Ciabatti, Giacomo Ercolano, et al.
Epigenomics|September 8, 2015
Polycomb genes are associated with response to imatinib in chronic myeloid leukemiaFrancesco Crea, Antonello Di Paolo, Hui Hsuan Liu, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trialEmilio Iannitto, Viviana Minardi, Paolo G Gobbi, et al.
Journal of Human Genetics|January 11, 2013
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortiumAlessandro Martino, Juan Sainz, Rui Manuel Reis, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemiaLaura Galeotti, Francesco Ceccherini, Dario Domingo, et al.
Frontiers in Oncology|July 12, 2019
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid LeukemiaSusanna Grassi, Sara Palumbo, Veronica Mariotti, et al.
Muscle & Nerve|January 22, 2011
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter studyAdriano Chiò, Gabriele Mora, Vincenzo La Bella, et al.
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
International Journal of Oncology|December 14, 2011
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review)Alessandro Martino, Juan Sainz, Gabriele Buda, et al.
Cancer Cell International|April 18, 2019
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patientsSerena Salehzadeh, Francesca Guerrini, Umberto Pizzano, et al.
Pageof 26